AstraZeneca has started late-stage trials of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.
Categories
AstraZeneca starts new COVID-19 prevention trials of antibody cocktail